GlaxoSmithKline, Europe's biggest drugmaker, said on Tuesday it had applied for a licence to sell a non-prescription weight-loss pill in Europe.
GlaxoSmithKline said its application for a licence to sell the over-the-counter (OTC) medicine, known as Alli in the United States, had been accepted by the European Agency for the Evaluation of Medicinal Products (EMEA).
Alli, the only non-prescription weight-loss remedy with U.S. Food and Drug Administration approval, was launched in the United States in June and recorded sales of 76 million pounds ($156 million) in the second quarter.
"If people are looking for a quick fix, this is not it. But it is a powerful motivator, helping people lose up to 50 percent more weight than with diet alone," John Clarke, President GSK Consumer Healthcare, said in a statement.
More at Reuters
No comments:
Post a Comment